Antiangiogenic therapies: Is VEGF-A inhibition alone enough?

Expert Review of Anticancer Therapy

Volumn 11, Issue 3, 2011, Pages 485-496

  Gordon, Michael S ^a  

^a Pinnacle Oncology Hematology   (United States)

Author keywords

adnectin; antiangiogenesis; CT 322; VEGF A; VEGFR inhibitors

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CT 322; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; PTC 299; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VATALANIB;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BILE DUCT CANCER; BLEEDING; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CARDIOTOXICITY; COLORECTAL CANCER; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; DRUG WITHDRAWAL; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; NEUROENDOCRINE TUMOR; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PHARMACOLOGICAL BLOCKING; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; PROTEINURIA; REBOUND; RECURRENT CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; THROMBOSIS; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952960682     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.5     Document Type: Review

References (115)

1. Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc. Am. Thorac. Soc. 6(2), 206-217 (2009)
2. Gutierrez M, Giaccone G. Antiangiogenic therapy in nonsmall cell lung cancer. Curr. Opin. Oncol. 20(2), 176-182 (2008) (Pubitemid 351317405)
3. Los M, Roodhart JM, Voest EE. Target practice: lessons from Phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12(4), 443-450 (2007) (Pubitemid 46698722)
4. Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 29(11), 1159-1168 (2007) (Pubitemid 350057387)
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82(1), 4-6 (1990) (Pubitemid 20020880)
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000)
7. Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer 100(1), 19-23 (2009)
8. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683-2710 (2007) (Pubitemid 350070717)
9. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized Phase II study. J. Clin. Oncol. 27(15), 2523-2529 (2009)
10. Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J. Gastroenterol. 13(44), 5857-5866 (2007) (Pubitemid 350148502)
11. Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a Phase I/II clinical trial. Clin. Cancer Res. 5(Suppl. 10), 3190s-3198s (1999) (Pubitemid 29493915)
12. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232-239 (2009)
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003) (Pubitemid 36749215)
14. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs 16(1), 83-107 (2007) (Pubitemid 44964169)
15. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2049 (2008) (Pubitemid 351656458)
16. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 17(3), 499-512 (2010)
17. Kopfstein L, Veikkola T, Djonov VG, et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol. 170(4), 1348-1361 (2007) (Pubitemid 47339341)
18. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39(5), 469-478 (2006) (Pubitemid 44714526)
19. Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4), 399-411 (2009)
20. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56(3), 794-814 (1999) (Pubitemid 29411709)
21. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12(17), 5018-5022 (2006) (Pubitemid 44453326)
22. Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat. Clin. Pract. Oncol. 4(3), 181-189 (2007) (Pubitemid 46358855)
23. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res. 3(6), 861-865 (1997) (Pubitemid 27252933)
24. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer 86(4), 558-563 (2002) (Pubitemid 34185092)
25. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. 19(2), 432-441 (2001) (Pubitemid 32112856)
26. Oka N, Soeda A, Inagaki A, et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem. Biophys. Res. Commun. 360(3), 553-559 (2007) (Pubitemid 47048135)
27. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56(9), 2185-2190 (1996) (Pubitemid 26119923)
28. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 6(10), 569-579 (2009)
29. Teramoto S, Arihiro K, Koseki M, Kataoka T, Asahara T, Ohdan H. Role of vascular endothelial growth factor-C and -D mRNA in breast cancer. Hiroshima J. Med. Sci. 57(2), 73-78 (2008)
30. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7(2), 186-191 (2001) (Pubitemid 32148485)
31. Achen MG, Williams RA, Minekus MP, et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J. Pathol. 193(2), 147-154 (2001) (Pubitemid 32118124)
32. Bahram F, Claesson-Welsh L. VEGFmediated signal transduction in lymphatic endothelial cells. Pathophysiology 17(4), 253-261 (2009)
33. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 41(4), 278-286 (2008) (Pubitemid 351656921)
34. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer 115(1), 140-148 (2009)
35. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7(6), 504-516 (2008) (Pubitemid 351767118)
36. Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind Phase III trial (ZEST). J. Clin. Oncol. 27(15S), (2009) (Abstract 8009)
37. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, doubleblind Phase III trial (ZEAL). J. Clin. Oncol. 27(15S), (2009) (Abstract 8010)
38. Herbst R, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind Phase III trial (ZODIAC). J. Clin. Oncol. 27(18S), (2009) (Abstract CRA8003)
39. Miller VA, O?Connor PG, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(18S), (2009) (Abstract LBA8002)
40. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008)
41. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007) (Pubitemid 46089672)
42. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007) (Pubitemid 46089673)
43. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as secondline treatment of colorectal cancer. Oncologist 12(3), 356-361 (2007) (Pubitemid 46556802)
44. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004) (Pubitemid 38702844)
45. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23(15), 3502-3508 (2005)
46. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007) (Pubitemid 46733080)
47. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008)
48. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15(3), 167-170 (2009)
49. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009)
50. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin. Ther. Targets 13(4), 455-468 (2009)
51. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6(6), 327-338 (2009)
52. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3(6), 401-410 (2003) (Pubitemid 37328844)
53. Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23(4), 792-799 (2005) (Pubitemid 46224178)
54. Tang TC, Man S, Xu P, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12(11), 928-940 (2010)
55. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116(10), 2610-2621 (2006) (Pubitemid 44511625)
56. Bagri A, Berry L, Gunter B, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin. Cancer Res. 16(15), 3887-3900 (2010)
57. Cacheux W, Boisserie T, Staudacher L, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann. Oncol. 19(9), 1659-1661 (2008)
58. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5(3), 203-220 (2007) (Pubitemid 46569773)
59. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 15(2), 130-141 (2010)
60. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 10(6), 559-568 (2009)
61. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 7(6), 475-485 (2007) (Pubitemid 46809172)
62. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007)
63. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6), 713-718 (2007) (Pubitemid 47036205)
64. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006) (Pubitemid 44917502)
65. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 15(1), 104-111 (2010)
66. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon a-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007) (Pubitemid 350296300)
67. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009)
68. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11), 1131-1138 (2009)
69. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006) (Pubitemid 43108832)
70. Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin. Cancer Res. 10(12 Pt 2), 4258s-4262s (2004) (Pubitemid 38812458)
71. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAiL). Ann. Oncol. 21(9), 1804-1809 (2010)
72. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumabcontaining treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14(9), 862-870 (2009)
73. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20(11), 1842-1847 (2009)
74. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26(33), 5326-5334 (2008)
75. Allegra CJ, Yothers G, O?Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. 29(1), 11-16 (2010)
76. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26(30), 4899-4905 (2008)
77. Garcia-Saenz JA, Martin M, Calles A, et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer. J. Chemother. 20(5), 632-639 (2008)
78. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer 101(12), 1986-1994 (2009)
79. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27(20), 3312-3318 (2009)
80. Beck J, Bajetta E, Escudier B, et al. A large open label, non comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Presented at: 14th European Cancer Conference. Barcelona, Spain, 23-27 September 2007
81. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5), 1272-1280 (2010)
82. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol. 10(1), 25-34 (2009)
83. Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multi-targeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a Phase 2 study (SOGUG-02-06). Lancet Oncol. 11(4), 350-357 (2010)
84. Hsu CH, Shen YC, Lin ZZ, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J. Hepatol. 53(1), 126-131 (2010)
85. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21), 2516-2524 (2006) (Pubitemid 43854967)
86. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006) (Pubitemid 46630489)
87. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584-3590 (2009)
88. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329-1338 (2006) (Pubitemid 44528723)
89. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010)
90. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebocontrolled, Phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 3)
91. Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, Phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J. Clin. Oncol. 24(Suppl. 18), 3508 (2006) (Abstract 3508)
92. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007) (Pubitemid 46075199)
93. Joly A. Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects. Eur. J. Cancer Suppl. 4(12), 35 (2006)
94. de Groot JF, Prados M, Urquhart T, et al. A Phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J. Clin. Oncol. 27(15S), (2009) (Abstract 2047)
95. Kurzrock R, Sherman SI, Pfister D, et al. Preliminary results of a Phase 1 study of XL184, a MET, VEGFR2 and RET kinase inhibitor, administered orally to patients with thyroid cancer (TC). Presented at: 34th Annual Meeting of the European Thyroid Association. Lisbon, Portugal, 5-9 September 2009
96. Gordon M, Edelman G, Galsky M, et al. An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients with advanced solid tumors J. Clin. Oncol. 28(15S), (2010) (Abstract TPS188)
97. Huynh H, Fargnoli J. Brivanib alaninate. Drugs Future 34(11), 881 (2009)
98. Bhide RS, Lombardo LJ, Hunt JT, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer Ther. 9(2), 369-378 (2010)
99. Jonker DJ, Rosen LS, Sawyer MB, et al. A Phase I study to determine the safety, pharmacokinetics, and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann. Oncol. DOI: 10.1093/annonc/mdq599 (2010) (Epub ahead of print)
100. Raoul J-L, Lencioni R, Baudelet C, Walters I. Tumor response in a Phase 2 study of first-and second-line brivanib in hepatocellular carcinoma (HCC): comparison of modified WHO and modified RECIST criteria. Presented at: 45th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, 14-18 April 2010
101. Mamluk R, Carvajal IM, Morse BA, et al. Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2 MAbs. DOI: 10.4161/mabs.2.2.11304 (2010) (Epub ahead of print)
102. Marathe P, Tang Y, Sleczka B, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J. Pharm. Sci. 98(8), 3579-3593 (2010)
103. Bahleda R, Soria J, Harbison C, et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J. Clin. Oncol. 27(15S), (2009) (Abstract 8098)
104. Hirawat S, Elfring GL, Northcutt VJ, et al. Phase I studies assessing the safety, PK, and VEGF-modulating effects of PTC299, a novel VEGF expression inhibitor. J. Clin. Oncol. 25(18S), (2007) (Abstract 3562)
105. Davis TW, Weetall M, Pagel MD, et al. Preclinical efficacy of PTC299, an antiangiogenic candidate in clinical development for the treatment of breast cancer. Presented at: American Society of Clinical Oncology (ASCO) 2007 Breast Cancer Symposium. San Francisco, CA, USA, 7-8 September 2007
106. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102(1), 8-18 (2010)
107. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat. Clin. Pract. Oncol. 4(9), 536-550 (2007) (Pubitemid 47351464)
108. Fojo T. Commentary: novel therapies for cancer: why dirty might be better. Oncologist 13(3), 277-283 (2008) (Pubitemid 351679902)
109. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 10(5), 484-495 (2010)
110. Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy 2(3), 367-379 (2010)
111. Tumor rebound -is there clinical evidence? Eticho (European Training in Clinical Hematology and Oncology) Meeting Slides-Angiogenesis 2009 www.eticho.org/angio2009-Meeting%20.slides
112. Roche provides results on Avastin in adjuvant colon cancer. Roche Investor Update www.roche.com/investors/ir-update/inv-update-2010-2009-18b.htm
113. ® in advanced hepatocellular carcinoma. Pfizer Press Release http://media.pfizer.com/files/ news/press-releases/2010/sun-1170-042210.pdf ASK Pfizer discontinues global Phase III trial of axitinib for futility in advanced pancreatic cancer. Medical News Today www.medicalnewstoday.com/articles/137485.php (Accessed 11 March 2010)
114. RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer www.astrazeneca.com/Media/Pressreleases/Article/20100308- RECENTINdid-not-meet-primary-endpoint-in-Horizon-III
115. PTC299. PTC Therapeutics www.ptcbio.com/3.1.2-oncology.aspx (Accessed 11 March 2010)